Overview
Sermorelin is the truncated 1-29 fragment of growth hormone-releasing hormone — the region identified as containing the complete receptor-binding pharmacophore of the full 44-amino-acid hormone. That makes it a natural comparator in structure-activity studies asking which portions of the GHRH sequence are necessary and sufficient for receptor activation, and one of the most extensively characterized GHRH analogs in pituitary biology research.
Mechanism of Action
Sermorelin binds GHRHR on anterior pituitary somatotroph preparations, activating Gs-coupled adenylyl cyclase and intracellular cAMP accumulation; downstream PKA activity triggers GH granule exocytosis in a pattern consistent with native receptor stimulation. Released GH subsequently drives hepatic IGF-1 production through JAK2/STAT5 signaling in target tissue models. Lacking N-terminal stability modifications, its shorter half-life suits pulsatile secretion modeling and time-course designs where stimulation duration must be tightly controlled.
Specifications
- Purity: ≥99% (HPLC) with mass-spectrometry identity confirmation
- Form: Lyophilized powder
- CAS Number: 86168-78-7
- Molecular Weight: ~3357.9 g/mol
- Chemical Formula: C₁₄₉H₂₄₆N₄₄O₄₂S
- Synonyms: GHRH(1-29)-NH₂, GRF(1-29)
Research Applications
- GHRHR binding kinetics and receptor pharmacology
- Pulsatile GH secretion and pulse-dynamics modeling
- GH/IGF-1 axis and JAK2/STAT5 pathway studies
- GHRH fragment structure-activity research
- Neuroprotective and metabolic pathway models





